Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2041)	2/9/2017 2:37:13 PM
From: Miljenko Zuanic	Respond to of 3559

Damage to Praluent is already done and will increase in coming months. But, there is a chance that it may reverse after Praluent CVOT is out. First, let see first Repatha complete data (dose, sub-endoints, safety,...), and than comment further. Regards the appeals, the best chances are in invalidating certain claims in patents, but what are time-frame sequence for thoes appeals I have no data. Maybe someone have? Dev? From the current bio-sector perspective (and what emerge from current administration in 17/18... ), seems to me that REGN is well positioned.But, I my be biased here.